'Immunexcite'[s] investors, pads coffers with $8.6M A-1 round
Immunexcite Inc. completed an $8.6 million series A-1 financing, topping off a series of smaller rounds that sustained the immuno-oncology (I-O) company and its technology, dubbed Mabxcite, for more than five years. All told, the Lexington, Mass.-based company has raised more than $15 million since it was incorporated in 2007, mostly beginning with a $2.4 million series A at the end of 2011.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST